Alnylam Officials Tout End of Novartis Alliance as Opportunity to Focus on Pipeline

Included in Alnylam's pipeline is a preclinical program in hypercholesterolemia, which remains on track to yield an investigational new drug application filing next year and will incorporate a new lipid-nanoparticle delivery technology developed in collaboration with Tekmira Pharmaceuticals.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.